CPP11G

CPP11G is a selective, brain-penetrant small molecule inhibitor of NADPH oxidase 2 (Nox2) developed as a research compound, primarily at the University of Pittsburgh. It belongs to the bridged tetrahydroisoquinoline class and acts by disrupting the protein-protein interaction between the p47phox subunit and the Nox2-p22phox complex. This mechanism prevents the translocation of p47phox to the plasma membrane, which is a critical step for the assembly and activation of the Nox2 enzyme complex. By inhibiting Nox2, CPP11G reduces the production of reactive oxygen species (ROS) and attenuates downstream inflammatory signaling pathways, including MAPK, AP-1, and NFκB. Preclinical research has demonstrated its potential in treating inflammatory conditions, endothelial cell inflammation, vascular dysfunction, and neurodegenerative diseases such as Alzheimer's and Parkinson's disease. It is currently available only for research purposes and has not been approved for human use.